If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Growth-hormone-releasing peptide-6
Batch documentation
Ask sales for the GHRP-6 COA matched to the offered batch. Review the recorded tests, specifications, and results against your QA and destination-market requirements before quotation.
Overview
GHRP-6 is a synthetic hexapeptide GHSR agonist within the GHRP family. What distinguishes it from its siblings (GHRP-2, Ipamorelin, Hexarelin) is a pronounced appetite-stimulating effect that runs alongside the GH-release activity. The appetite signal traces to GHRP-6's binding profile at the GHSR sitting in the hypothalamic arcuate nucleus, native ghrelin is the body's endogenous hunger hormone, and GHSR agonists at higher doses partially recapitulate the appetite-driving activity that ghrelin natively delivers. The published research therefore covers two distinct lanes: GH-release pharmacology and orexigenic applications, making this molecule the right tool when both effects are desired and the wrong tool when either is a confounder. Vialdyne releases GHRP-6 as a lyophilised powder against a ≥99.0% main-peak HPLC specification. SPPS access to the hexapeptide is straightforward, so the standard release packet centres on peak-integration RP-HPLC plus ESI-MS identity. Catalogue strengths are 5 mg and 10 mg, sized to typical bench-scale research workflows. Selection rule: appetite-pharmacology endpoints point to GHRP-6 as the cleanest GHRP-family choice; clean GH-selective work points to Ipamorelin instead, both the appetite and cortisol-axis effects of GHRP-6 become contamination in that context.
Applications & buyer fit
GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want loose-format lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.
Sourced for
Buyer fit
Documentation that ships
Procurement note: For sterile-filled vials, confirm whether sterility, endotoxin, and CCI are included in the agreed release packet. For loose lyophilized powder, request the batch COA and separately scope any sequence-level evidence required by the buyer's written procedure.
Primary buyer fit: academic and contract research laboratories.
Specifications
Nasal spray listing · US inventory
GHRP-6 is also listed in this catalog as a nasal spray solution.

Batch COAs and test reports
Each picture is a low-resolution preview of a report's first page, with batch and report numbers covered. For the full, clear report, ask our sales team, naming the product and strength.
Batch COAGHRP-6 5 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COAGHRP-6 10 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Independent test fails? Full refund. How it works
Browse all COAs and reportsRegulatory note
Sold as a pharmaceutical-grade active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.
Selected literature
Frequently asked questions
Appetite stimulation is the defining feature. At typical research doses, GHRP-6 produces measurable orexigenic activity that GHRP-2 carries in smaller magnitude and Ipamorelin essentially lacks. The mechanism is binding at the hypothalamic-arcuate-nucleus GHSR, the same receptor through which endogenous ghrelin drives hunger signalling. The trade-off is a less GH-selective pharmacology than Ipamorelin: any cellular or in vivo readout sensitive to appetite-axis effects or cortisol-axis effects will pick up confounding signal from GHRP-6 that Ipamorelin would not contribute. The practical decision: appetite-pharmacology research points to GHRP-6, clean GH-selective work points to Ipamorelin.
For multi-use stocks, reconstitute in bacteriostatic water for injection (BWFI); for single-use preparation, use sterile water for injection (SWFI). The hexapeptide goes into solution within 30-60 seconds with a gentle swirl. Never vortex, the foaming entrains air and accelerates surface-mediated aggregation, which can show up as quiet potency loss the standard release HPLC will not flag. Sub-divide the reconstituted solution into single-use aliquots immediately and hold at -20 C with strict thaw-count discipline; as with the rest of the GHRP family, freeze-thaw cycle count dominates measured-potency loss in routine use, much more than slow temperature drift. Working-stock concentrations of 1-5 mg/mL are typical; for in vivo administration the working concentration is further diluted to the protocol-specified dose volume.
Yes. GHRP-6 is listed as a nasal spray solution (5 mg, 10 mg), filled in 10 mL or 20 mL bottles, with an MOQ of 10 bottles per content and fill. It is dispatched within the United States from US inventory; send an inquiry for current availability.
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
Related peptides